This paper aims to describe retinal changes during Spectral Domain Optical Coherence Tomography (SD-OCT) guided Bevacizumab treatment for neovascular age- related macular degeneration (AMD).

Material and Methods:

47 eyes of 45 patients with wet AMD treated on demand with Bevacizumab. We used 3-dimensional SD-OCT to measure photoreceptor defects and subretinal fibrosis. The main efficacy endpoints were the SD-OCT measurements of the size of photoreceptor defects, the size of external membrane defects and the central retinal thickness. Secondary endpoints were changes in visual acuity and the number of Bevacizumab injections over 12 months.


In long-term anti-VEGF treatment for neovascular AMD, photoreceptor defects and fibrosis progress despite a decrease in central retinal thickness and improvements in visual acuity. We would encourage further discussion as to whether this is the natural course of the disease or a result of the treatment.